融资方面，益诺思当日融资买入777.79万元。当前融资余额8854.22万元，占流通市值的2.51%。 融券方面，益诺思9月10日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元。 9月10日，益诺思涨3.57%，成交额7945.68万元。两融数据显示，当日益诺思获融资买入额777.79万 元，融资偿还470.41万元，融资净买入307.38万元。截至9月10日，益诺思融资融券余额合计8854.22万 元。 截至6月30日，益诺思股东户数5386.00，较上期减少0.90%；人均流通股5235股，较上期增加0.91%。 2025年1月-6月，益诺思实现营业收入3.75亿元，同比减少38.04%；归母净利润-1518.95万元，同比减少 115.88%。 分红方面，益诺思A股上市后累计派现4511.35万元。 机构持仓方面，截止2025年6月30日，益诺思十大流通股东中，工银医疗保健股票（000831）位居第七 大流通股东，持股43.94万股，相比上期增加7.23万股。工银战略转型股票A（000991）位居第九大流通 股东，持股35.41万股 ...

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2][3] - As of September 2, Yinosh's stock price fell by 2.24%, with a trading volume of 58.6354 million yuan. The net financing buy was -3.902 million yuan, indicating a higher repayment than new purchases [1] - Yinosh's financing balance reached 86.1492 million yuan, accounting for 7.59% of its market capitalization, with no short selling activity reported on the same day [1] Group 2 - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - As of June 30, 2025, the number of Yinosh shareholders was 5,386, a decrease of 0.90%, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - Yinosh has distributed a total of 45.1135 million yuan in dividends since its A-share listing, with changes in institutional holdings noted among its top shareholders [3]

Company Overview - Yinos Biotech Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company is set to be listed on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in the biopharmaceutical sector [1] - The revenue composition of Yinos is as follows: non-clinical services account for 95.42%, clinical services for 4.11%, and other services for 0.47% [1] Stock Performance - On September 1, Yinos shares increased by 5.1%, reaching a price of 40.98 CNY per share, with a trading volume of 30.95 million CNY and a turnover rate of 2.75%. The total market capitalization is 5.777 billion CNY [1] Shareholder Information - Among the top ten circulating shareholders of Yinos, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit for today is approximately 685,200 CNY [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current size of 786 million CNY. Year-to-date returns are 42.3%, ranking 534 out of 4222 in its category. Over the past year, returns are 50.75%, ranking 1765 out of 3779, and since inception, the fund has achieved a return of 93.9% [2] Fund Management - The fund manager for Harvest Medical Health Stock A is Sun Xiaohui, who has been in position for 144 days, with a total fund size of 985 million CNY. The best return during his tenure is 37.64%, while the worst is 37.22% [3] - The other fund manager, Hao Miao, has been in position for 6 years and 230 days, managing a total fund size of 3.652 billion CNY. His best return during his tenure is 183.83%, while the worst is -30.4% [3]

Summary of Key Points Core Viewpoint - Next week, 29 stocks in the A-share market will face a lock-up expiration, with a total of 2.013 billion shares being unlocked, amounting to a market value of approximately 18.877 billion yuan, representing a week-on-week decrease of 73.51% [1][2]. Company-Specific Summaries - **Foton Motor**: The largest stock by market value to be unlocked next week, with an unlock value of 3.957 billion yuan and 1.429 billion shares set to be released on September 3, 2025. The shares are from a targeted placement to institutional investors at an issue price of 2.10 yuan per share [2][4]. - **Futian Technology**: The second-largest unlock value at 2.887 billion yuan, with 0.079 billion shares to be released on September 4, 2025. The shares include original shareholders' restricted shares and strategic placement shares [2][4]. - **Yinose**: The third-largest unlock value at 2.437 billion yuan, with 0.062 billion shares to be released on September 3, 2025, also consisting of original shareholders' restricted shares and strategic placement shares [2][4]. Market Performance - As of August 29, 2023, the stock price of Foton Motor was 2.77 yuan per share, with a market capitalization of approximately 21.9 billion yuan. The stock has seen a return of over 30% since the targeted placement, resulting in a floating profit of over 900 million yuan for the major shareholder, Beijing Automotive Group [4]. - Futian Technology's stock price was 36.63 yuan per share, with a market capitalization of about 5.7 billion yuan. Since its listing, the stock has appreciated over 260% compared to its issue price, indicating significant gains for strategic placement shareholders [4]. Unlocking Impact - Six stocks will see their unlock quantities exceed 30% of their total share capital, including Futian Technology (50.71%), Yinose (44.33%), Wufangzhai (37.61%), Sudar (36.76%), Liren Technology (34.81%), and Aopumai (31.83%). The unlocking will lead to a substantial increase in their circulating shares, with four stocks experiencing an increase of over 100% in their circulating market [7][8].

Core Viewpoint - Next week, 29 stocks in the A-share market will face a lock-up expiration, with a total of 2.013 billion shares being unlocked, amounting to a market value of 18.877 billion yuan, which represents a week-on-week decrease of 73.51% [1][3]. Summary by Category Unlocking Stocks - The stocks with the highest unlocking market value include Foton Motor at approximately 4 billion yuan, Fute Technology at 2.887 billion yuan, and Yinos at 2.437 billion yuan [2][3]. - Foton Motor will unlock 1.429 billion shares on September 3, 2025, all from a targeted placement to institutional investors [3][5]. - Fute Technology will unlock 0.079 billion shares on September 4, 2025, consisting of original shareholders' restricted shares and strategic placement shares [3][5]. - Yinos will unlock 0.062 billion shares on September 3, 2025, also from original shareholders' restricted shares and strategic placement shares [3][5]. Market Performance - As of August 29, the stock price of Foton Motor was 2.77 yuan per share, with a market capitalization of approximately 21.9 billion yuan [6]. - The stock price of Fute Technology was 36.63 yuan per share, with a market capitalization of about 5.7 billion yuan [6]. - The stock performance for the month of August shows Foton Motor with a gain of 2.97%, Fute Technology with a gain of 7.04%, and Yinos with a decline of 13.12% [3]. Increase in Circulation - Among the 29 stocks facing unlocking, six stocks will see their circulation increase by more than 30%, including Fute Technology (50.71%), Yinos (44.33%), Wufangzhai (37.61%), Suda Shares (36.76%), Liren Technology (34.81%), and Aopumai (31.83%) [10][11]. - Four of these stocks will experience a circulation increase of over 100% after the unlocking [10].

Group 1 - The core viewpoint of the report indicates a significant decline in the company's financial performance for the first half of 2025 compared to the same period in 2024, with a notable drop in revenue and net profit [2][3]. - Total assets at the end of the reporting period amounted to approximately 3.21 billion RMB, showing a slight decrease of 0.20% from the previous year [2]. - The company's operating income was reported at approximately 375.23 million RMB, reflecting a decrease of 38.04% year-on-year [2]. Group 2 - The total profit for the period was approximately 536.15 thousand RMB, which represents a drastic decline of 99.49% compared to the previous year [2]. - The net profit attributable to shareholders was reported as a loss of approximately 15.19 million RMB, marking a decrease of 115.88% from the same period last year [2]. - The company’s research and development expenditure as a percentage of operating income increased to 5.94%, up by 2.27 percentage points from the previous year [2]. Group 3 - The weighted average return on equity decreased to -0.64%, down by 6.37 percentage points compared to the previous year [2]. - The basic and diluted earnings per share were both reported at -0.11 RMB, a decline of 112.22% from the previous year [2]. - The total number of shareholders at the end of the reporting period was 5,386 [2].

Meeting Information - The shareholder meeting is scheduled for September 23, 2025, at 14:30 [1] - The meeting will be held at the Center Report Hall, 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone [1] - Voting will be conducted through both on-site and online methods [1] Voting Procedures - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system [1] - Voting will be available from 9:15 to 15:00 on the day of the meeting [1] - Shareholders can vote via the trading system or the internet voting platform [2][3] Shareholder Participation - Only shareholders registered by the close of trading on September 15, 2025, are eligible to attend the meeting [5] - Shareholders can appoint proxies to attend and vote on their behalf [4][5] Meeting Registration - Shareholders must register in advance to attend the meeting [5][6] - Registration requires identification and proof of shareholding [6] Additional Information - The company will provide reminder services to facilitate participation from small and medium investors [3] - Transportation and accommodation costs for attending shareholders are self-funded [6]

Group 1 - The third meeting of the supervisory board of Shanghai Yinos Biotech Co., Ltd. was held on August 27, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report, affirming that the report accurately reflects the company's operational management and financial status for the first half of 2025 [1][2] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations and that there were no misrepresentations or omissions [2][4] Group 2 - The supervisory board agreed to the proposal for the reappointment of the accounting firm, which will be submitted for approval at the company's third extraordinary general meeting of shareholders in 2025 [3] - The board approved the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and increase returns on cash assets, while ensuring the protection of shareholder interests [3][4]

Group 1 - The core revenue of the company for the first half of 2025 reached 375 million yuan, with new orders amounting to 532 million yuan, reflecting a year-on-year increase of 7.39% [1] - The total backlog of orders stood at 1.112 billion yuan, which is a 14.29% increase compared to the end of 2024 [1] - The company experienced growth across all business segments, with a combined year-on-year increase of 6.86% in new projects for IND and NDA applications [1] Group 2 - The company is a leading comprehensive R&D service provider in the biopharmaceutical non-clinical research sector, recognized for its international service capabilities [2] - As of June 30, 2025, the company has successfully assisted in over 200 innovative drug research services, including several groundbreaking therapies and products [2] - The strategic project in Nantong has been successfully implemented, covering an area of 24,000 square meters and featuring 130 international standard animal housing units, which will enhance the company's capacity and efficiency in innovative molecules and advanced therapies [2]

从销售端来看，2025年公司各业务板块齐头并进，其中核心业务IND(新药临床试验申请)和NDA(新药上 市申请)的新签项目个数合计同比增长6.86%，彰显了公司强大的市场拓展能力。 2025年上半年，公司研发投入占营业收入的比例由上年的3.67%提升至5.94%，同比提升2.27个百分点。 在业绩承压的背景下，公司仍坚守稳定的研发投入规模，既体现了对技术创新的持续重视，也彰显了企 业务实创新的核心理念与对自身长期发展潜力的坚定信心。报告期内，公司新授权发明专利1项。截至 报告期末，公司拥有已授权的专利共计69项。 益诺思作为一家专业的提供生物医药非临床研究服务为主的综合研发服务(CRO)企业，是国内最早同时 具备NMPA的GLP认证、OECD的GLP认证、通过美国FDA的GLP检查的企业之一，与国际标准接轨， 具备了行业内具有竞争力的国际化服务能力，为全球的医药企业和科研机构提供全方位的符合国内国际 申报标准的一站式新药研发服务。 特别值得一提的是，公司海外布局成效显著，国际业务新签订单同比大幅增长，公司在国际市场上的认 可度和影响力逐步提升。其通过在核心业务领域的深耕细作与市场拓展策略的有效实施，在服务的客 ...